Browsing Tag
Medtronic
24 posts
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Can Nia’s 60-channel brain implant redefine closed-loop neuromodulation in memory therapy?
Nia Therapeutics validates its wireless brain implant for closed-loop memory stimulation. Find out how it could transform treatment for traumatic brain injury.
From Medtronic to the market: What MiniMed’s IPO means for CGM and insulin pump competition
Medtronic files IPO for MiniMed, its diabetes device business. Find out what this spin-off could mean for the future of CGM and insulin delivery tech.
Anteris Technologies launches its pivotal trial phase for DurAVR THV, marking a regulatory turning point
Anteris Technologies launches the global PARADIGM pivotal trial of its DurAVR THV, challenging Edwards and Medtronic with biomimetic valve durability data—see how the race unfolds.
Johnson & Johnson to spin off DePuy Synthes, creating the world’s largest standalone orthopaedics company
Find out how Johnson & Johnson’s DePuy Synthes spin-off reshapes the $9 billion orthopaedics market and accelerates the company’s innovation focus.
Medtronic (NYSE: MDT) launches Embrace Gynecology study — will Hugo RAS redefine robotic hysterectomies in the U.S.?
Medtronic’s Embrace Gynecology trial tests Hugo RAS in hysterectomies—can it challenge da Vinci’s dominance and reshape women’s robotic surgery?
Is neuromodulation entering its next growth cycle? Lessons from Medtronic, Axonics, and Boston Scientific
Neuromodulation is moving into its next growth cycle. Explore how Medtronic, Boston Scientific, and Axonics are reshaping bladder control and chronic care.
From stigma to scale: How bladder control therapies are evolving from hidden struggle to healthcare priority
Bladder control therapies are moving from stigma to mainstream care. Discover how rising awareness and innovation are reshaping treatment options globally.
Medtronic stock dips even as FDA clears Altaviva device for bladder control breakthrough
Medtronic (NYSE: MDT) wins FDA approval for Altaviva, a minimally invasive bladder control device. Find out why the stock fell and what it means for investors.
Medtronic receives FDA clearance for innovative Smart MDI system with Simplera CGM integration
Medtronic plc has received U.S. Food and Drug Administration (FDA) clearance for its innovative Smart Multiple Daily Injection…